Literature DB >> 11564809

Passively acquired antibodies suppress humoral but not cell-mediated immunity in mice immunized with live attenuated respiratory syncytial virus vaccines.

J E Crowe1, C Y Firestone, B R Murphy.   

Abstract

A respiratory syncytial virus (RSV) vaccine will need to be administered by 1 mo of age to protect young infants; therefore, it will need to be effective in the presence of maternally acquired RSV Abs. In the present study, the immunogenicity and efficacy of two live attenuated RSV vaccine candidates of different level of attenuation were evaluated in mice passively immunized with varying quantities of RSV Abs. The replication of the RSV vaccines was suppressed in the lower, but not the upper, respiratory tract of the passively immunized mice. Immunization with either vaccine candidate was highly efficacious against challenge with wild-type RSV in both passively immunized and control mice. Nonetheless, a high level of immunity was seen even in passively/actively immunized animals that failed to develop a humoral immune response, suggesting that T cells mediated the immunity. Depletion of CD4+ and CD8+ T cells in passively/actively immunized and control animals at the time of challenge with wild-type RSV demonstrated that CD4+ and CD8+ T cells made significant independent contributions to the restriction of replication of RSV challenge virus in both the upper and lower respiratory tracts. Although passively acquired serum RSV Abs suppressed the primary systemic and mucosal Ab responses of IgM, IgG, and IgA isotypes, B lymphocytes were nevertheless primed for robust secondary Ab responses. Thus, immunity mediated by CD4+ and CD8+ T cells and Abs can be readily induced in mice by live RSV vaccine candidates in the presence of physiologic levels of RSV neutralizing Abs.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11564809     DOI: 10.4049/jimmunol.167.7.3910

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  39 in total

Review 1.  Genetic and structural determinants of virus neutralizing antibodies.

Authors:  J E Crowe; R O Suara; S Brock; N Kallewaard; F House; J H Weitkamp
Journal:  Immunol Res       Date:  2001       Impact factor: 2.829

Review 2.  New generation live vaccines against human respiratory syncytial virus designed by reverse genetics.

Authors:  Peter L Collins; Brian R Murphy
Journal:  Proc Am Thorac Soc       Date:  2005

3.  The role of maternal antibodies in the emergence of severe disease as a result of fragmentation.

Authors:  David Fouchet; Stéphane Marchandeau; Nargès Bahi-Jaber; Dominique Pontier
Journal:  J R Soc Interface       Date:  2007-06-22       Impact factor: 4.118

Review 4.  Nonsegmented negative-strand viruses as vaccine vectors.

Authors:  Alexander Bukreyev; Mario H Skiadopoulos; Brian R Murphy; Peter L Collins
Journal:  J Virol       Date:  2006-11       Impact factor: 5.103

Review 5.  Viral and host factors in human respiratory syncytial virus pathogenesis.

Authors:  Peter L Collins; Barney S Graham
Journal:  J Virol       Date:  2007-10-10       Impact factor: 5.103

6.  Maternally transferred anti-factor VIII IgG reduce the anti-factor VIII humoral immune response in factor VIII-deficient mice.

Authors:  Yann Meslier; Sébastien André; Maud Teyssandier; Srinivas V Kaveri; Sébastien Lacroix-Desmazes
Journal:  Immunology       Date:  2010-12       Impact factor: 7.397

7.  Seroprevalence of pandemic (H1N1) 2009 influenza and effectiveness of 2010/2011 influenza vaccine during 2010/2011 season in Beijing, China.

Authors:  Peng Yang; Li Zhang; Weixian Shi; Guilan Lu; Shujuan Cui; Xiaomin Peng; Daitao Zhang; Yimeng Liu; Huijie Liang; Xinghuo Pang; Quanyi Wang
Journal:  Influenza Other Respir Viruses       Date:  2011-12-30       Impact factor: 4.380

8.  RNA interference inhibits respiratory syncytial virus replication and disease pathogenesis without inhibiting priming of the memory immune response.

Authors:  Wenliang Zhang; Ralph A Tripp
Journal:  J Virol       Date:  2008-09-25       Impact factor: 5.103

9.  An alphavirus replicon-based human metapneumovirus vaccine is immunogenic and protective in mice and cotton rats.

Authors:  Hoyin Mok; Sharon J Tollefson; Amy B Podsiad; Bryan E Shepherd; Vasiliy V Polosukhin; Robert E Johnston; John V Williams; James E Crowe
Journal:  J Virol       Date:  2008-09-10       Impact factor: 5.103

10.  Influence of respiratory syncytial virus strain differences on pathogenesis and immunity.

Authors:  José A Melero; Martin L Moore
Journal:  Curr Top Microbiol Immunol       Date:  2013       Impact factor: 4.291

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.